34.42
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics Inc. Stock Analysis and ForecastUnmatched market gains - PrintWeekIndia
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales - MSN
Is Viking Therapeutics Inc. a good long term investmentPhenomenal investment performance - PrintWeekIndia
H.C. Wainwright Reiterates a Buy Rating on Viking Therapeutics (VKTX), Sets a $102 PT - MSN
Viking Therapeutics Q2: Confidently Continuing The Recovery (NASDAQ:VKTX) - Seeking Alpha
Analysts Are Bullish on These Healthcare Stocks: Thermo Fisher (TMO), Viking Therapeutics (VKTX) - The Globe and Mail
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Gilead Sciences (GILD) - The Globe and Mail
Viking Therapeutics Receives Buy Rating Amid Promising Clinical Developments and Strategic Initiatives - TipRanks
What drives Viking Therapeutics Inc. stock priceAccelerated wealth expansion - PrintWeekIndia
Viking Therapeutics stock maintains Buy rating at Stifel on obesity drug potential - Investing.com Australia
Viking Therapeutics’ Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
Viking Therapeutics EPS miss sends shares down 7% - MSN
Viking Therapeutics Surges to 433rd in Trading Volume as Strategic Partnership and Clinical Success Fuel Stock Rally - AInvest
Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity - insights.citeline.com
Viking Therapeutics (VKTX) Stock Rating Maintained by Raymond James | VKTX Stock News - GuruFocus
Viking Therapeutics Q2 Earnings Miss Estimates, R&D Expenses Rise - AInvest
Viking Therapeutics stock rating reiterated by Cantor Fitzgerald at $104 - Investing.com Canada
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Insider Monkey
Viking Therapeutics outlines Phase III VANQUISH trial enrollment of 5,600 patients while advancing oral obesity program - MSN
Viking Therapeutics Inc (VKTX) Q2 2025 Earnings Call Highlights: Navigating Increased R&D ... - Yahoo Finance
Viking Therapeutics Inc (VKTX) Q2 2025 Earnings Call Highlights: - GuruFocus
Viking Therapeutics Advances Clinical Pipeline Amid Financial Losses - TipRanks
Viking Therapeutics' Q2 2025 Earnings Call: Unpacking Key Contradictions in Phase III Study Strategy - AInvest
What analysts say about Viking Therapeutics Inc. stockSuperior stock selection - jammulinksnews.com
Viking Therapeutics Posts Wider Q2 Loss - AOL.com
Viking Therapeutics EPS miss sends shares down 7% (VKTX:NASDAQ) - Seeking Alpha
Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates - Benzinga
Viking Therapeutics (VKTX) Reports Q2 Loss, Misses EPS Expectati - GuruFocus
Viking Therapeutics, Inc. SEC 10-Q Report - TradingView
Viking Therapeutics shares fall as Q2 loss exceeds estimates By Investing.com - Investing.com India
Viking (VKTX) Q2 2025 Earnings Call Transcript - Mitrade
Viking Therapeutics reports Q2 EPS (58c), consensus (44c) - TipRanks
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | VKTX Stock News - GuruFocus
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Finansavisen
Viking Therapeutics (VKTX) Options Activity Surges Ahead of Earnings | VKTX Stock News - GuruFocus
Viking Therapeutics to Report Q2 2025 Financial Results on July 23, 2025 - AInvest
Viking Therapeutics, Inc. (NASDAQ:VKTX) institutional owners may be pleased with recent gains after 38% loss over the past year - Yahoo Finance
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 - Finansavisen
Viking Therapeutics (VKTX) Set to Release Q2 Earnings Results - GuruFocus
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - Mitrade
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):